170 related articles for article (PubMed ID: 17414324)
1. Pretreatment levels of sTNF-R1 and sIL-6R are associated with a higher vulnerability for IFN-alpha-induced depressive symptoms in patients with malignant melanoma.
Friebe A; Schwarz MJ; Schmid-Wendtner M; Volkenandt M; Schmidt F; Horn M; Janssen G; Schaefer M
J Immunother; 2007 Apr; 30(3):333-7. PubMed ID: 17414324
[TBL] [Abstract][Full Text] [Related]
2. Baseline mood and psychosocial characteristics of patients developing depressive symptoms during interleukin-2 and/or interferon-alpha cancer therapy.
Capuron L; Ravaud A; Miller AH; Dantzer R
Brain Behav Immun; 2004 May; 18(3):205-13. PubMed ID: 15050647
[TBL] [Abstract][Full Text] [Related]
3. Depressive mood changes and psychiatric symptoms during 12-month low-dose interferon-alpha treatment in patients with malignant melanoma: results from the multicenter DeCOG trial.
Heinze S; Egberts F; Rötzer S; Volkenandt M; Tilgen W; Linse R; Boettjer J; Vogt T; Spieth K; Eigentler T; Brockmeyer NH; Hinzpeter A; Hauschild A; Schaefer M
J Immunother; 2010 Jan; 33(1):106-14. PubMed ID: 19952950
[TBL] [Abstract][Full Text] [Related]
4. Correlation between sICAM-1 and depressive symptoms during adjuvant treatment of melanoma with interferon-alpha.
Schaefer M; Horn M; Schmidt F; Schmid-Wendtner MH; Volkenandt M; Ackenheil M; Mueller N; Schwarz MJ
Brain Behav Immun; 2004 Nov; 18(6):555-62. PubMed ID: 15331126
[TBL] [Abstract][Full Text] [Related]
5. Persistent inflammation and its relationship to leptin and insulin in phases of bipolar disorder from acute depression to full remission.
Tsai SY; Chung KH; Huang SH; Chen PH; Lee HC; Kuo CJ
Bipolar Disord; 2014 Dec; 16(8):800-8. PubMed ID: 25130211
[TBL] [Abstract][Full Text] [Related]
6. Lipid Peroxidation and Immune Biomarkers Are Associated with Major Depression and Its Phenotypes, Including Treatment-Resistant Depression and Melancholia.
Sowa-Kućma M; Styczeń K; Siwek M; Misztak P; Nowak RJ; Dudek D; Rybakowski JK; Nowak G; Maes M
Neurotox Res; 2018 Feb; 33(2):448-460. PubMed ID: 29103192
[TBL] [Abstract][Full Text] [Related]
7. Depression in hospitalized patients with malignant melanoma treated with interferon-alpha-2b: primary to induced disorders.
Navinés R; Gómez-Gil E; Puig S; Baeza I; De Pablo J; Martín-Santos R
Eur J Dermatol; 2009; 19(6):611-5. PubMed ID: 19709980
[TBL] [Abstract][Full Text] [Related]
8. Comparison of pro-inflammatory cytokines among patients with bipolar disorder and unipolar depression and normal controls.
Bai YM; Su TP; Li CT; Tsai SJ; Chen MH; Tu PC; Chiou WF
Bipolar Disord; 2015 May; 17(3):269-77. PubMed ID: 25257835
[TBL] [Abstract][Full Text] [Related]
9. Safety of pegylated interferon-alpha-2a in adjuvant therapy of intermediate and high-risk melanomas.
Loquai C; Nashan D; Hensen P; Luger TA; Grabbe S; Sunderkötter C; Schiller M
Eur J Dermatol; 2008; 18(1):29-35. PubMed ID: 18086586
[TBL] [Abstract][Full Text] [Related]
10. Dose-dependent development of depressive symptoms during adjuvant interferon-{alpha} treatment of patients with malignant melanoma.
Friebe A; Horn M; Schmidt F; Janssen G; Schmid-Wendtner MH; Volkenandt M; Hauschild A; Goldsmith CH; Schaefer M
Psychosomatics; 2010; 51(6):466-73. PubMed ID: 21051677
[TBL] [Abstract][Full Text] [Related]
11. Comparison of inflammatory cytokine levels among type I/type II and manic/hypomanic/euthymic/depressive states of bipolar disorder.
Bai YM; Su TP; Tsai SJ; Wen-Fei C; Li CT; Pei-Chi T; Mu-Hong C
J Affect Disord; 2014 Sep; 166():187-92. PubMed ID: 25012430
[TBL] [Abstract][Full Text] [Related]
12. Adjuvant therapy of melanoma with interferon-alpha-2b is associated with mania and bipolar syndromes.
Greenberg DB; Jonasch E; Gadd MA; Ryan BF; Everett JR; Sober AJ; Mihm MA; Tanabe KK; Ott M; Haluska FG
Cancer; 2000 Jul; 89(2):356-62. PubMed ID: 10918166
[TBL] [Abstract][Full Text] [Related]
13. Changes in sIL-6R and sTNF-Rs release by PMNs and the serum levels in breast cancer patients at different stages of treatment.
Jablonska E
Cytokine; 1998 Jul; 10(7):540-3. PubMed ID: 9702418
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of Inflammatory Response System (IRS) and Compensatory Immune Response System (CIRS) in Adolescent Major Depression.
Ferencova N; Visnovcova Z; Ondrejka I; Funakova D; Hrtanek I; Kelcikova S; Tonhajzerova I
J Inflamm Res; 2022; 15():5959-5976. PubMed ID: 36303711
[TBL] [Abstract][Full Text] [Related]
15. Self-efficacy for coping with cancer in melanoma patients: its association with physical fatigue and depression.
Albrecht K; Droll H; Giesler JM; Nashan D; Meiss F; Reuter K
Psychooncology; 2013 Sep; 22(9):1972-8. PubMed ID: 23288588
[TBL] [Abstract][Full Text] [Related]
16. Interferon-alpha in oncology patients: fewer psychiatric side effects than anticipated.
Bannink M; Kruit WH; Van Gool AR; Sleijfer S; van der Holt B; Eggermont AM; Stoter G; Hengeveld MW
Psychosomatics; 2008; 49(1):56-63. PubMed ID: 18212177
[TBL] [Abstract][Full Text] [Related]
17. Neurobehavioral effects of interferon-alpha in cancer patients: phenomenology and paroxetine responsiveness of symptom dimensions.
Capuron L; Gumnick JF; Musselman DL; Lawson DH; Reemsnyder A; Nemeroff CB; Miller AH
Neuropsychopharmacology; 2002 May; 26(5):643-52. PubMed ID: 11927189
[TBL] [Abstract][Full Text] [Related]
18. Cytokines, cytokine antagonists and soluble adhesion molecules in patients with ocular Behçet's disease treated with human recombinant interferon-alpha2a. Results of an open study and review of the literature.
Kötter I; Koch S; Vonthein R; Rückwaldt U; Amberger M; Günaydin I; Zierhut M; Stübiger N
Clin Exp Rheumatol; 2005; 23(4 Suppl 38):S20-6. PubMed ID: 16273760
[TBL] [Abstract][Full Text] [Related]
19. Soluble fractions of tumor necrosis factor-alpha, interleukin-6 and of their receptors in toxic epidermal necrolysis: a comparison with second-degree burns.
Paquet P; Piérard GE
Int J Mol Med; 1998 Feb; 1(2):459-62. PubMed ID: 9852250
[TBL] [Abstract][Full Text] [Related]
20. Serum TNF-α, B2M and sIL-2R levels are biological correlates of outcome in adjuvant IFN-α2b treatment of patients with melanoma.
Hofmann MA; Kiecker F; Küchler I; Kors C; Trefzer U
J Cancer Res Clin Oncol; 2011 Mar; 137(3):455-62. PubMed ID: 20454974
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
